Should You Buy ImageneBio, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, ImageneBio, Inc. (IMA) carries a solid Quality of Company rating of 5.7/10. Trading at $4.92, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 0 of 0 CirclFi valuation models project upside for ImageneBio, Inc. (IMA) at $4.92 — the models are evenly split, with a Quality Score of 5.7/10 and Value-Trap risk of 63/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for ImageneBio, Inc. (IMA) in 2026?
What Is the Bull Case vs the Bear Case for ImageneBio, Inc. (IMA)?
| Bull case | Bear case |
|---|---|
| No active model projects meaningful upside for IMA at $4.92. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | No active model flags significant downside for IMA. The Value Trap score of 63/100 still argues for some caution. |
How Does IMA Compare to Its Biotechnology Peers?
Valuation data pages: NRXS · OVID · FTRE · AUTL · CGON · UPB · CMPX · HUMA · SPRO · EXEL · INCY
Which Other Stocks Score Like IMA on Quality?
Closest companies to IMA’s Quality of Company score of 5.7/10, across all industries.
Which Biotechnology Screens Does IMA Appear In?
So Is ImageneBio, Inc. (IMA) Worth Buying in 2026?
ImageneBio, Inc. currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.
These are quantitative model outputs, not investment recommendations. ImageneBio, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About IMA Stock?
Should I buy IMA stock right now?
Based on CirclFi's multi-model analysis, 0 of 0 models see upside for IMA at $4.92. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in ImageneBio, Inc.?
Key risks include: an elevated Value Trap score of 63/100, suggesting apparent undervaluation may mask deteriorating fundamentals; limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does IMA compare to its competitors?
Among Biotechnology peers, IMA holds a Quality Score of 5.7/10. Comparable companies include NRXS (QOC 5.7), OVID (QOC 5.7), FTRE (QOC 5.7). The relative ranking helps investors identify whether IMA offers better fundamental quality than alternatives in the same sector.
Is IMA a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. IMA's Quality Score of 5.7/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy IMA at?
CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for IMA.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad